Digital health funding in the first quarter of 2026 reached $7.4 billion, marking a significant rebound from the $5.9 billion recorded in the fourth quarter of 2025 and representing the highest level since the second quarter of 2022, according to a CB Insights report cited by multiple industry analyses.
This surge was driven largely by a resurgence in mergers and acquisitions activity, with 56 deals closed during the quarter—a 47% increase from the previous period—and a pronounced shift toward “mega-rounds” of $100 million or more. Nineteen such mega-rounds accounted for 60% of all capital raised, reflecting a continued concentration of investment in fewer, larger bets.
The median late-stage deal size more than doubled year-over-year, rising to $108 million from $48 million in Q4’25, while eight new unicorns were minted in Q1 2026—the highest single-quarter count in nearly four years. Abbott’s $23 billion acquisition of Exact Sciences stood as the quarter’s largest transaction, aimed at expanding the global reach of Exact Sciences’ Cologuard colorectal cancer screening technology.
Another notable deal was DeepHealth’s $269 million acquisition of Gleamer, which was motivated by Gleamer’s established footprint across more than 700 hospital contracts, underscoring a broader market trend where commercial adoption is now prioritized over mere regulatory clearance in M&A strategy.
Despite the influx of capital, significant challenges persist in healthcare AI readiness. Less than 20% of enterprise healthcare data is currently suitable for AI applications without substantial preparation, due to inconsistencies such as mixed temperature units and non-standardized free-text diagnosis codes. Most electronic health record (EHR) and customer relationship management (CRM) systems were originally designed for billing, compliance, or sales tracking rather than predictive modeling, creating a structural barrier to AI integration.
Healthcare now accounts for nearly half of all vertical AI spending globally, with projections indicating AI investment in the sector will reach $1.5 billion in 2025—more than triple the $450 million spent the prior year. This growing focus on AI-driven drug discovery and clinical decision support has attracted major venture capital interest, particularly in North America, which captured 76% of global digital health venture funding in Q1 2026, amounting to $5.37 billion across 114 deals.
Europe followed with 17% of venture capital, or $1.16 billion across 66 deals. Within the sector, Health Management Solutions emerged as the leading category, attracting $1.01 billion in funding (14.2% of VC capital), closely followed by Patient Solutions at $983 million (13.9%) and Wellness at $790 million (11%).
The quarter also saw one initial public offering—Generate Biomedicines raised $400 million—and exit activity totaled $3.5 billion across 47 transactions, including 46 M&A acquisitions. When combined with post-exit transactions such as the Rznomics strategic investment agreement valued at $1.3 billion, total exit and post-exit activity reached $5.1 billion across 48 transactions.
These figures bring combined digital health activity—encompassing venture funding, M&A, IPOs, and post-exit deals—to $12.2 billion across 263 transactions in Q1 2026, reflecting a maturing market where later-stage companies are scaling with substantial war chests. Firms like Devoted Health and Alan now operate with over $100 million in available capital, enabling them to remain private while pursuing distribution expansion and strategic acquisitions.
Industry analysts note that while funding momentum has returned, the sector remains top-heavy, with capital increasingly concentrated among a small number of high-value deals. This trend raises questions about equitable access to innovation and the long-term sustainability of a funding model dominated by mega-rounds and late-stage dominance.
As digital health continues to evolve, stakeholders are watching for the next wave of clinical validation studies and real-world evidence reports expected throughout the second and third quarters of 2026, which will be critical in determining whether current investments translate into measurable improvements in patient outcomes and system efficiency.
For ongoing updates on digital health trends, funding flows, and regulatory developments, readers are encouraged to follow authoritative sources such as CB Insights, Rock Health, and Galen Growth, which provide regular, data-driven analyses of the sector.
Join the conversation: Share your thoughts on how concentrated funding might shape the future of digital health innovation in the comments below, and help spread awareness by sharing this article with colleagues and networks interested in healthcare transformation.